OXYFEDRINE HYDROCHLORIDE, DL-

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H23NO3.ClH
Molecular Weight	349.852
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of OXYFEDRINE HYDROCHLORIDE, DL-

Structure Search

SMILES

Cl.COC1=CC=CC(=C1)C(=O)CCN[C@@H](C)[C@H](O)C2=CC=CC=C2

InChI

InChIKey=JMUPNNYLJGSMPK-JPJJPTBZSA-N

InChI=1S/C19H23NO3.ClH/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2;/h3-10,13-14,19-20,22H,11-12H2,1-2H3;1H/t14-,19-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H23NO3
Molecular Weight	313.3908
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1801897 | https://www.ncbi.nlm.nih.gov/pubmed/7437255

Oxyfedrine, an amino ketone derivative and partial agonist at beta receptors, has been shown to have potent antianginal properties and to increase coronary blood flow in normal and ischemic myocardial regions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87 Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6095552 \| https://www.ncbi.nlm.nih.gov/pubmed/20326 \| http://www.drugsupdate.com/generic/view/377/Oxyfedrine	Partial Agonist 290

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1801897 https://www.ncbi.nlm.nih.gov/pubmed/4874592 https://www.ncbi.nlm.nih.gov/pubmed/4874592	Primary		Approved 8429	Ildamen Approved Use Angina pectoris
Myocardial infarction 121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/359492	Primary		Approved 8429	Oxyfedrine Approved Use Myocardial infarction

PubMed

Title	Date	PubMed
[The management of angina pectoris using Ildamen, a new coronary- and cardiac-active substance, in a double-blind study].	1967 Sep 10	4874592
[Stimulation of adrenergic beta-receptors in the heart of normal and reserpinized guinea pigs by oxyfedrine].	1969 Sep	5394533
Pulmonary and systemic circulatory effects and -adrenergic selectivity of hexoprenaline, salbutamol, oxyfedrine, and isoproterenol.	1971 Jul	5153847
Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease.	1991 Dec	1801897

Patents

Sample Use Guides

In Vivo Use Guide

Oral Myocardial infarction, Angina pectoris Adult: 8-24 mg tid.

Route of Administration: Oral

In Vitro Use Guide

Oxyfedrine was tested in vitro against 471 strains of bacteria from two Gram positive and fourteen Gram negative genera. The minimum inhibitory concentration (MIC) of oxyfedrine was determined by agar dilution method, which ranged from 50-200 ug/ml in most of the strains, while some strains were inhibited at even lower concentrations.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:49:29 GMT 2023` Edited by `admin` on `Sat Dec 16 09:49:29 GMT 2023`
Record UNII	H1CAC99B4D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYFEDRINE HYDROCHLORIDE, DL-

Common Name

English

DL-OXYFEDRINE HYDROCHLORIDE

Common Name

English

OXYFEDRINE DL-FORM HYDROCHLORIDE [MI]

Common Name

English

OXYFEDRINE DL-FORM HYDROCHLORIDE

Common Name

English

1-PROPANONE, 3-(((1R,2S)-2-HYDROXY-1-METHYL-2-PHENYLETHYL)AMINO)-1-(3-METHOXYPHENYL)-, HYDROCHLORIDE (1:1), REL-

Systematic Name

English

MYOFEDRIN

Common Name

English

Code System Code Type Description

FDA UNII

H1CAC99B4D